Scholars Central

Conference abstractPublished 22 Jun 2017

Genetic determinants of methotrexate toxicity in Tunisian patients with rheumatoid arthritis: A study of polymorphisms in key methotrexate pathway genes

Authors: Abdellatif Maalej, Souhir Chaabane, Sameh Marzouk, Rim Akrout, Mariem Ben Hamad, Yosser Achour, Ahmed Rebai, Leila Keskes, Hela Fourati, Zouhir Bahloul

Laboratory of Human Molecular Genetics, Faculty of Medicine, Sfax, Tunisia; University Hospital Hedi Chaker, Sfax, Tunisia; Department of Bioinformatics, Center of Biotechnology, Sfax, Tunisia

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Introduction: Methotrexate (MTX) is a disease-modifying anti-rheumatic drug used in the treatment of rheumatoid arthritis (RA). It is the first line drug in the treatment of this disease. However, MTX-related adverse drug reactions (ADRs) are present in 40% of the patients. Aim: The purpose of this study was to investigate the influence of genetic polymorphisms in genes involved in the folate metabolic pathway (MTHFR, DHFR), methionine pathway (MTR, MTRR), pyrimidine synthesis (TYMS) and the MTX transport pathway (RFC1, ABCB1, ABCC2) on the occurrence of MTX-related toxicity (overall and gastrointestinal) and to identify pharmacogenetic markers of MTX toxicity in a group of Tunisian RA patients. Methods: A total of 182 patients with rheumatoid arthritis, under MTX treatment were investigated in this study. Clinicopathological data were collected and ADRs were recorded. A genotyping approach was performed using PCR, PCRRFLP and TaqMan allelic discrimination method to determine the studied polymorphisms. Association analyses with regard to MTX-related toxicity were evaluated using ÏÂ?2 test, genotype relative risk (GRR) and the toxicogenetic risk index (TRI). Results: Statistical analysis revealed that RFC1 80G/G genotype had increased risk of gastrointestinal toxicity (p=0.032), as well as the T/T genotype of MTHFR C677T polymorphism was associated with both overall and gastrointestinal toxicity (p=0.0007), while TYMS 2RâÂ?Â?3R polymorphism had a protective effect against overall MTX toxicity (p=0.031). However, we did not find any association of the MTHFR A1298C, DHFR 19âÂ?Â?base pair deletion allele, MTR A2756G, MTRR A66G, ABCB1 C3435T and ABCC2 G1249A polymorphisms with MTX toxicity. Conclusion: This study demonstrated that genotyping of MTHFR C677T and RFC1 G80A may be a possible predictor to identify patients with increased risk for developing overall and gastrointestinal toxicity related to MTX treatment in Tunisian patients.

Subjects

Toxicology

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Clinical Toxicology.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Clinical Toxicology
  • SubjectToxicology
  • BylineArticles whose byline prints “Abdellatif Maalej”
  • BylineArticles whose byline prints “Souhir Chaabane”
  • BylineArticles whose byline prints “Sameh Marzouk”
  • BylineArticles whose byline prints “Rim Akrout”
  • BylineArticles whose byline prints “Mariem Ben Hamad”
  • BylineArticles whose byline prints “Yosser Achour”
  • BylineArticles whose byline prints “Ahmed Rebai”
  • BylineArticles whose byline prints “Leila Keskes”